Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Stomach Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Non-small Cell Lung Cancer Metastatic 1Neoplasms by Site 1Neoplasms 1Mesothelioma, Malignant 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Advanced Solid Tumor 1Adenocarcinoma Gastric 1Adenocarcinoma 1

Interventions

Paclitaxel 4tocilizumab 2pembrolizumab 2atezolizumab 2zansecimab 1tivozanib 1temsirolimus 1spartalizumab 1ridaforolimus 1parsaclisib 1olaparib 1obinutuzumab 1motesanib diphosphate 1liposomal doxorubicin 1itacitinib 1epacadostat 1durvalumab 1birinapant 1Vertebroplasty 1Temozolomide 1TAK-981 1Ramucirumab 1Panobinostat 1Oxaliplatin 1Leucovorin 1Kyphoplasty 1IT-101 1INCB039110 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Solid Tumors × Ramucirumab × Clear all
NCT02597036 2025-10-23

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
62 enrolled 25 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡